LL/2 (LLC1) Syngeneic Model Overview
The LL/2 (LLC1) syngeneic model is a well-characterized murine system of non–small cell lung carcinoma (NSCLC) derived from a spontaneous alveolar carcinoma in C57BL/6 mice. It is one of the most widely utilized models in preclinical oncology for evaluating immunotherapies, targeted treatments, and combination regimens involving radiation or chemotherapy. LL/2 tumors demonstrate aggressive growth, robust vascularization, and moderate immune responsiveness, making this system highly relevant for investigating immune evasion, tumor hypoxia, and metastatic progression in an immunocompetent background.
Following subcutaneous or orthotopic implantation into C57BL/6 mice, LL/2 tumors exhibit reproducible growth kinetics and form vascularized lesions with an active tumor–stroma interface. The model’s metastatic capacity, especially through hematogenous dissemination to the lungs and liver, enables studies of both primary tumor control and secondary site colonization. The LL/2 (LLC1) model remains one of the most versatile murine lung cancer systems for preclinical research, supporting investigations of immune checkpoint blockade, myeloid cell reprogramming, and the immunologic effects of standard cytotoxic agents.
Request a Custom Quote for LL/2 (LLC1) Syngeneic ModelBiological and Molecular Characteristics
The LL/2 (LLC1) cell line originates from a spontaneous alveolar carcinoma in C57BL/6 mice and exhibits epithelial morphology consistent with undifferentiated NSCLC. It lacks hormone receptor expression and demonstrates a gene expression profile indicative of high angiogenic and inflammatory activity. The model displays upregulation of VEGF, CXCL1, and IL-6, which promote vascularization, myeloid recruitment, and tumor progression. Despite its aggressive phenotype, the LL/2 tumor maintains partial immune recognition and responsiveness to T-cell–mediated attack, providing a valuable balance between tumor robustness and immunogenicity.
The immune microenvironment is dominated by myeloid-derived suppressor cells (MDSCs) and macrophages, along with infiltrating T lymphocytes and dendritic cells. This composition reproduces the immunosuppressive milieu typical of advanced-stage lung cancer in patients. The model’s immunological complexity and reproducible kinetics make it particularly suitable for assessing novel immunotherapeutic agents, angiogenesis inhibitors, and microenvironment-targeted therapies.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Spontaneous alveolar carcinoma (mouse) |
| Histological type | Poorly differentiated non–small cell lung carcinoma |
| Inoculation route | Subcutaneous, orthotopic, or intravenous |
| Tumor take rate | >95% |
| Doubling time | Approximately 2–3 days in vivo |
| Metastatic potential | High; lung and liver metastases common |
| Immunophenotype | Myeloid-rich, partially immunogenic tumor microenvironment |
| Common applications | Immunotherapy, angiogenesis, metastasis, and combination therapy studies |
In Vivo Model Development and Tumorigenicity
LL/2 tumors are typically established by subcutaneous or orthotopic implantation of viable cells into C57BL/6 mice, with tumor nodules appearing within 4–6 days after inoculation. Subcutaneous implantation allows for direct tumor volume monitoring and is commonly used for immunotherapy screening, whereas orthotopic implantation into the lung parenchyma offers a physiologically relevant model of primary pulmonary carcinoma with spontaneous metastasis. Intravenous injection is also used to generate pulmonary colonization models for metastasis and anti-angiogenic drug evaluation.
The LL/2 (LLC1) model exhibits rapid tumor progression, enabling short experimental timelines and high reproducibility across studies. Its aggressive growth and angiogenic activity make it particularly well suited for evaluating the effects of immune checkpoint blockade in combination with vascular-targeted agents or chemotherapy. Because it grows in an immunocompetent host, the model supports comprehensive assessment of T-cell activity, macrophage polarization, and myeloid suppression during tumor evolution.
Request a Custom Quote for LL/2 (LLC1) Syngeneic ModelHistopathology and Immunohistochemical Profile
Histologically, LL/2 tumors are composed of poorly differentiated epithelial cells with a high nuclear-to-cytoplasmic ratio and frequent mitotic figures. Tumor sections reveal extensive vascularization, areas of necrosis, and a prominent fibroblastic stroma. The microenvironment is infiltrated by macrophages, neutrophils, and lymphocytes, forming a dense interface between tumor cells and host tissue. This histological profile is representative of high-grade NSCLC, characterized by active angiogenesis and stromal remodeling.
Immunohistochemical staining demonstrates high Ki-67 expression, indicative of strong proliferative capacity. F4/80 and CD11b staining identify abundant macrophage and myeloid populations, while CD3 and CD8 reveal moderate T-cell infiltration within tumor parenchyma. PD-L1 expression is typically elevated and inducible by interferon signaling, particularly in response to immunotherapy or radiation. The histological and immunohistochemical features of LL/2 tumors mirror those of aggressive lung carcinoma, providing a translationally relevant framework for studying immune modulation and therapy-induced changes in the tumor microenvironment.
Preclinical Applications and Drug Response
The LL/2 (LLC1) syngeneic model is widely utilized for evaluating immunotherapies, anti-angiogenic agents, and combination treatment regimens in lung cancer research. It exhibits moderate responsiveness to immune checkpoint inhibitors targeting PD-1 and PD-L1, with enhanced efficacy observed when combined with chemotherapy, radiotherapy, or cytokine agonists. The model’s strong angiogenic signature has made it a standard system for testing VEGF and VEGFR inhibitors, as well as vascular-disrupting agents.
LL/2 tumors also serve as a platform for exploring mechanisms of immune resistance and macrophage-driven immune suppression. Studies using this model have demonstrated that reprogramming tumor-associated macrophages or inhibiting myeloid-derived suppressor cell recruitment can restore anti-tumor immunity and improve checkpoint blockade outcomes. Due to its aggressive phenotype, immunocompetent background, and compatibility with genetic manipulation of C57BL/6 mice, the LL/2 (LLC1) model remains one of the most important murine systems for preclinical evaluation of lung cancer immunotherapies.
Request This Model
To request the LL/2 (LLC1) syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for LL/2 (LLC1) Syngeneic Model